Bespoke Extracts, Inc. Announces Financial Results and Strategic Rebranding for the First Quarter Ended March 31, 2025

AURORA, Colo., July 01, 2025 (GLOBE NEWSWIRE) -- Bespoke Extracts, Inc. (OTCQB:BSPK), a Colorado based company focused on operating in the regulated cannabis markets in the United States, today announced its financial results for the first quarter ended March 31, 2025, and highlighted the successful rebranding of its product offerings under The Joint Company.

Financial Highlights for Q1 2025:

Revenue Growth: Sales increased to $263,159, up 1.0% from $260,428 in Q1 2024, fueled by strong direct sales of branded pre-rolled joints and expanded joint production services for licensed dispensaries in Colorado.

Improved Gross Profit: Gross profit rose to $110,779 from $102,581 in Q1 2024, driven by enhanced production efficiencies in pre-rolled joints, though partially offset by higher packaging and testing costs for new product launches.

Reduced Operating Expenses: Operating expenses fell to $356,117 from $405,384 in Q1 2024, reflecting lower stock-based compensation, reduced salaries, and decreased professional fees.

Reduced Net Loss: Net loss decreased to $260,521, from $314,118 in Q1 2024.

Strategic Rebranding and Product Expansion under The Joint Company (TJC)

In Q1 2025, Bespoke Extracts successfully rebranded as The Joint Company (TJC), a pivotal step in its growth strategy. TJC scaled its white-label processing business and launched two new branded products, Doobskis and Dutch Blunts, which have gained significant traction in Colorado's regulated cannabis market. The Fresh Joint product line continues to increase product revenue, primarily through growth in multi-packs.

Operational Highlights:

Through its subsidiary, Bespoke Extracts Colorado, LLC, the Company operates a marijuana-infused products manufacturing facility in Aurora, selling its products and services to licensed dispensaries in Colorado.

Achieved cost efficiencies in raw materials, packaging, and labor, boosting gross margins despite increased marketing and sampling costs for new product launches.

Daily pre-roll production increased by 32% compared to Q1 2024, enhancing TJC's ability to offer competitive processing services and lower priced products in Colorado.

The Company is exploring expansion of TJC into other state-regulated cannabis markets, leveraging its successful Colorado operations experience to pursue new growth opportunities.

Management is focused on expanding market share and optimizing operations for sustainable, long-term growth.

Management Commentary:

Michael Feinsod, CEO of Bespoke Extracts, stated: "Q1 2025 marked a transformative period for Bespoke Extracts as we rebranded to The Joint Company and introduced Doobskis and Dutch Blunts. These initiatives, combined with enhanced third-party processing capabilities, have significantly strengthened our market position and revenue potential. Despite an 8.8% contraction in Colorado's regulated cannabis market during the quarter ending March 31, 2025 compared to Q1 2024, we achieved year-over-year growth. Our improved manufacturing processes are delivering strong results, and we expect continued gross margin improvements as we scale. We remain committed to disciplined financial management and strategic expansion in the regulated cannabis market."

Fiscal Q2 2025 Outlook:

Revenue Growth:    Based on preliminary Q2 2025 sales data, we have seen significant sales traction in our new product lines during the second quarter. The Company projects revenue exceeding $385,000 for the quarter ending June 30, 2025, compared to $278,163 in the quarter ended June 30, 2024, driven by continued growth of FreshJoints , strong demand for Doobskis and Dutch Blunts and expanded third-party processing services.

Operational Efficiencies: Continued improvements in manufacturing processes are expected to support higher production volumes and consistent product quality.

Gross Margin Improvement: Enhanced production efficiencies and cost management in raw materials, packaging, and labor are projected to drive higher gross margins, despite increased marketing investments for new product launches.

 

 

 

 

Balance SheetCondensed Consolidated Balance Sheets(unaudited)

 

 

 

 

 

March 31,2025

 

December 31,2024

Assets

 

 

 

Current assets

 

 

 

Cash

$

30,365

 

 

$

60,305

 

Accounts receivable, net

 

36,757

 

 

 

57,276

 

Prepaid Expense

 

17,094

 

 

 

15,150

 

Inventory, net

 

38,904

 

 

 

32,526

 

Total current assets

 

123,120

 

 

 

165,257

 

 

 

 

 

Furniture and equipment

 

29,557

 

 

 

31,342

 

License

 

10,000

 

 

 

10,000

 

Right of Use Asset

 

73,448

 

 

 

140,489

 

Deposits

 

12,000

 

 

 

12,000

 

Total assets

$

248,125

 

 

$

359,088

 

 

 

 

 

Liabilities and Stockholders' (Deficit)

 

 

 

Current liabilities